VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront

VOLITIONRX LTD

Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).
Cash & equivalents $10.9M at Dec 31, 2022; raised ~$8.0M net in Feb 2023 offering.
Heska agreement: $10M upfront received, up to $18M milestones; IDEXX launched Nu.Q Vet test.
Nu.Q NETs CE marked; FDA Breakthrough Device application expected H1 2023.
34 patent families, 97 granted patents; capital market day set for May 11, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VOLITIONRX LTD reported the full fiscal year ended December 31, 2022 results: revenue approximately $300,000.

Period: the full fiscal year ended December 31, 2022
Revenue: approximately $300,000
Result: reported results

Exact text from the filing

$8.0 million in net cash (before deducting offering expenses payable by Volition) through an underwritten public offering of its common stock. · Recorded approximately $300,000 in revenue in 2022, up 240% over the prior year. · Received a $10 million upfront payment on signing the Heska Licensing and Supply Agreement. · During 2022, strengthened its

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-23-001496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.